Outcome of patients with hepatitis C virus-related single, small hepatocellular carcinoma.
To clarify the cumulative recurrence-free interval and survival rate with hepatitis C virus (HCV)-related single, small hepatocellular carcinoma (HCC), we studied 32 patients with surgical resection, 61 with ablation therapy and 28 with transcatheter chemoembolization (TACE). A log-rank test revealed that there were no significant differences in the recurrence-free interval (p = 0.08) and survival (p = 0.279) between the resection and the ablation groups. Univariate analysis using the Cox proportional hazards regression model showed initial treatment (p = 0.0051) was associated with recurrence-free interval. Platelet count (p = 0.009), indocianine green retention rate at 15 minutes (p = 0.003), Child-Pugh classification (p = 0.001), serum albumin level (p = 0.0012) and serum total bililubin (p = 0.015) were associated with survival. Hence patients with HCV-related single, small HCC should be treated according to their hepatic reserve.
Sako
Katsumi
K
Division of Hepatology, Nanpuh Hospital, 14-3 Nagatacho, Kagoshima 892-8512, Japan. k-sako@nanpuh.or.jp
Komorizono
Yasuji
Y
Oketani
Makoto
M
Hasegawa
Susumu
S
Yamasaki
Naruhiro
N
Shibatou
Toshihiko
T
Maeda
Masahiko
M
Kohara
Kazunori
K
Shigenobu
Shuhou
S
Yasunari
Hiramine
H
Sakurai
Kazuhiro
K
Hiwaki
Takuya
T
Ishibashi
Kazuaki
K
Arima
Terukatsu
T
D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000601:surgery / Q000628:therapy* / Q000821:virology*; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D018572:Disease-Free Survival; D005260:Female; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D008113:Liver Neoplasms / Q000601:surgery / Q000628:therapy* / Q000821:virology*; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome